# OnCo record relugolix (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/relugolix/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "relugolix" ;
  schema:name "Relugolix"@en ;
  schema:description "Relugolix is the first hormone-suppressing pill for prostate cancer, working within days and wearing off quickly when stopped."@en ;
  schema:url <https://onco.cc/drugs/relugolix/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Relugolix> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21099000> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relugolix>, <https://www.nice.org.uk/guidance/ta995> ;
  onco:status "approved" ;
  onco:modality "Oral GnRH antagonist" ;
  schema:alternateName "Orgovyx" ;
  onco:approval "US 2020: Advanced prostate cancer" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:companies <https://onco.cc/companies/sumitomo-pharma/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/> ;
  onco:terms <https://onco.cc/terms/prostate-adt-burden/>, <https://onco.cc/terms/prostate-uk-drug-approvals/> ;
  onco:trials <https://onco.cc/trials/nct05862272/> .